Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) In 2021
Vertex Price Introduction!
Vertex Pharmaceuticals Inc. is priced at $213 at the exchange. The company stock rose to decent highs last year but has dropped in one year. Vertex has a day’s range of $213-$216 and a 52-week range of $203-$306. Vertex holds a market cap of $55B, with beta value of 0.67.
Based in Boston, Vertex is a biopharmaceutical company (top biopharma companies). It is one of the first biotech firms using an explicit strategy of rational drug designs instead of using a combination of different chemistries. Though Vertex itself is a sound name in the pharmaceutical industry, it faces strict competition from many names, which is now impeding the company’s business.
Are You Going To Consider Vertex Pharmaceuticals?
A high flying biotech, VRTX stock is currently undervalued at $213. Investors are worried about the company’s pipeline. In 2021 though, VRTX is trading 19 times higher than its price which is impressive. Looking ahead, demand for CF drugs will benefit Vertex given that the market is large.
Vertex is also interested in bolstering its pipeline by buying more assets. Furthermore, the company’s current commercial drugs such as those that fix Cystic Fibrosis are going to benefit the company now and in the future.
A Look At Vertex Ahead!
VRTX stock has underperformed the broader markets because of many factors. However, it is still in higher leagues because of being a manufacturer of many drugs today.
Vertex is still a biotech stock (top 2 biotech stocks) to buy in May. The company discovers and develops small molecule drugs in order to treat serious diseases. Its therapies remain a major standard of care. Since the company is leading the area of cystic fibrosis, especially in North America, Europe and Australia, Vertex could still have a lot coming up for itself in the near future.
Stay tuned more updates at Tech Unveiled.
614 total views, 1 views today